The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The move strengthens GBL’s clinical-stage presence in the United States
The combination also outperformed chemotherapy on another important secondary endpoint
Patients with BRCA mutations often face aggressive disease and poor prognosis
Bertozzi currently serves as the Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor at Stanford University, and Investigator of the Howard Hughes Medical Institute
Hansoh Pharma will receive an upfront payment in the low double-digit millions
India plays a critical role in Bristol Myers Squibb’s global strategy
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Subscribe To Our Newsletter & Stay Updated
